Skip to main content

Eton Pharmaceuticals, Inc.

corporate_fare Company Profile

Eton Pharmaceuticals, Inc.

ETON·NASDAQ·Life Sciences·CIK 0001710340

Eton is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently has eight commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. Eton also has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. INCRELEX® is a biologic product approved by the FDA in August 2005 for treating children with severe primary insulin-like growth factor 1 deficiency (SPIGFD). It is approved in 40 territories, including the United States and the European Union. Eton acquired and launched INCRELEX® in December 2024. ALKINDI SPRINKLE® was approved by the FDA in September 2020 as a replacement therapy for Adrenocortical Insufficiency ("AI") in children under 17 years of age. It is the first and only FDA-approved granule hydrocortisone formulation designed for accurate dosing in newborns and children with AI. Eton acquired U.S. marketing rights in March 2020 and launched ALKINDI SPRINKLE® in December 2020. The product is protected by three issued patents extending to 2032, 2033, and 2034. KHINDIVI TM was approved by the FDA in May 2025 as a replacement therapy for adrenocortical insufficiency in pediatric patients five years of age and older. It is the only FDA-approved oral solution formulation of hydrocortisone, available in a 1mg/ml strength. KHINDIVI is a ready-to-use oral liquid solution that does not require refrigeration, mixing, or shaking.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for ETON at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Eton Pharmaceuticals CBO Sells $3.23M in Stock After Option Exercise
  • Officer Files Intent to Sell $3.5M in Eton Pharmaceuticals Stock
  • Eton Pharmaceuticals Expands Rare Disease Portfolio with IMPAVIDO® Commercialization Rights
  • Eton Pharmaceuticals Adds Orphan Drug IMPAVIDO® to Rare Disease Portfolio via U.S. Commercialization Deal
  • Eton Pharmaceuticals Boosts 2026 Revenue Outlook to Over $120M on 73% Q1 Sales Jump

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$79.95M
Net Income
-$4.6M
Op. Cash Flow
$10.52M
Free Cash Flow
$10.19M
Gross Profit
$42.74M
Operating Income
-$844K
Cash & Equivalents
$25.94M
Total Debt
$30.56M
Debt / Equity
1.17×
Net Margin
-5.8%
Shares Outstanding
27.05M sh
Source: 10-K · filed 2026-03-19 · accession 0001437749-26-009059
$60.85
52-week range · as of 2026-11-05 $14.27 – $66.37
Market cap
$1.76B
Volume
562.7K (1.0× avg)
3-mo avg 563.9K
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ETON - Filings & News (Page 2)

ETON
May 27, 2026, 6:28 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $33.00
Real-time Price: $60.85 info
Change: +$27.85 (+84%) info
Market Cap: $1.755B info
ETON
May 22, 2026, 4:24 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $32.59
Real-time Price: $60.85 info
Change: +$28.26 (+87%) info
Market Cap: $1.755B info
ETON
May 19, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.46
Real-time Price: $60.85 info
Change: +$27.39 (+82%) info
Market Cap: $1.755B info
ETON
May 19, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $32.89
Real-time Price: $60.85 info
Change: +$27.96 (+85%) info
Market Cap: $1.755B info
ETON
May 14, 2026, 4:17 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $30.70
Real-time Price: $60.85 info
Change: +$30.15 (+98%) info
Market Cap: $1.755B info
ETON
May 14, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.00
Real-time Price: $60.85 info
Change: +$29.85 (+96%) info
Market Cap: $1.755B info
ETON
May 01, 2026, 3:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $28.62
Real-time Price: $60.85 info
Change: +$32.24 (+113%) info
Market Cap: $1.755B info
ETON
Apr 27, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.02
Real-time Price: $60.85 info
Change: +$37.83 (+164%) info
Market Cap: $1.755B info
ETON
Apr 16, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.77
Real-time Price: $60.85 info
Change: +$34.08 (+127%) info
Market Cap: $1.755B info
ETON
Apr 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.97
Real-time Price: $60.85 info
Change: +$33.88 (+126%) info
Market Cap: $1.755B info
ETON
Mar 19, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $20.94
Real-time Price: $60.85 info
Change: +$39.92 (+191%) info
Market Cap: $1.755B info
ETON
Mar 19, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $20.94
Real-time Price: $60.85 info
Change: +$39.92 (+191%) info
Market Cap: $1.755B info
ETON
Mar 02, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.03
Real-time Price: $60.85 info
Change: +$43.82 (+257%) info
Market Cap: $1.755B info
ETON
Feb 25, 2026, 2:18 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $18.90
Real-time Price: $60.85 info
Change: +$41.96 (+222%) info
Market Cap: $1.755B info
ETON
Feb 02, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.01
Real-time Price: $60.85 info
Change: +$45.84 (+305%) info
Market Cap: $1.755B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets